MDOutlook presents the results from our innovative initiative of syndicated research gauging the clinical impact of new data presented at the 2016 ASCO Annual Meeting®. Supporting the entire cancer community and building on nearly 40 analyses since 2008, this is the third of four reports in our 2016 series covering clinical news presented in Chicago.
This OncoPoll™ focuses on non-prostate genitourinary cancers – both bladder and kidney cancers. It covers the expansion of the use of the checkpoint inhibitors into bladder cancer and renal cell carcinoma and the head-to-head comparison of cabozantinib vs. everolimus in the Meteor trial.
Our most recent research from a global panel of active genitourinary cancer treaters reveals:
• Oncologists see the use of the checkpoint inhibitors in bladder cancer as a very important clinical development, especially by those in the US. A slightly higher level of clinical importance to the checkpoint inhibitors are placed on their usage in 2nd+ lines of therapy, compared to the use of the 1st line
• The integration of the recently-approved atezolizumab into clinical practice has started off quickly, with 40% of US oncologists reporting their use of it in bladder cancer within the first month
• Oncologists are also enthusiastic about the use of nivolumab and cabozantinib as therapeutics for patients with RCC
• The interchangeability of checkpoint inhibitors is also explored in this report
Download your complimentary copy of our report MDOutlook June 2016 Oncopoll – GU Cancers.
MDOutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community.
To discuss your oncology and disease intelligence needs, please contact us at [email protected] or +1.404.496.4136. Thank you!
